Baseline demographics and disease characteristics of a subset of patients in a randomized, double-blind, placebo-controlled trial of etanercept in patients with psoriatic arthritis. The table includes patients with at least 1 HAQ-DI score showing improvement from baseline.
| Characteristic | Placebo, n = 69 | Etanercept, n = 92 | Total, n = 161 |
|---|---|---|---|
| Sex, n (%) | |||
| Men | 28 (41) | 50 (54) | 78 (48) |
| Race, n (%) | |||
| White | 63 (91) | 82 (89) | 145 (90) |
| African American | 2 (3) | 3 (3) | 5 (3) |
| Hispanic | 3 (4) | 6 (7) | 9 (6) |
| Other | 1 (1) | 1 (1) | 2 (2) |
| Age, mean (SD) yrs | 46.7 (11.1) | 46.9 (11.2) | 46.8 (11.1) |
| Baseline HAQ-DI, mean (range) | 1.17 (0.25–2.88) | 1.15 (0.13–2.50) | 1.16 (0.13–2.88) |
| Duration of PsA, yrs, mean (range) | 9.5 (0.2–35.4) | 8.8 (0.0–41.4) | 9.1 (0.0–41.4) |
HAQ-DI: Health Assessment Questionnaire Disability Index; PsA: psoriatic arthritis.